Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
compound inactivated staphylococcus albus
- Development stage
- Unknown
- Lead developer
- Shenhua Pharmaceutical
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Compound inactivated staphylococcus albus is an oral inactivated bacterial preparation developed and manufactured by Shenhua Pharmaceutical. It is primarily indicated for the treatment of chronic bronchitis and recurrent respiratory tract infections. The preparation consists of inactivated *Staphylococcus albus* (also known as *Staphylococcus epidermidis*), which acts as a non-specific immunomodulator. Upon oral administration, it stimulates the mucosal immune system, enhancing the phagocytic activity of macrophages and increasing the levels of secretory immunoglobulins (such as sIgA) in the respiratory tract. This helps to improve the body's resistance to bacterial and viral pathogens, reducing the frequency and severity of acute exacerbations of chronic respiratory conditions. In the Chinese pharmaceutical market, it is often formulated as a powder (Compound Inactivated Staphylococcus Albus Powder) which is then processed into tablets.
- Brand names
- Shenhua
- Other names
- Compound Inactivated Staphylococcus Albus TabletsCompound Inactivated Staphylococcus Albus Powder复方白葡萄球菌粉复方白葡萄球菌片Inactivated Staphylococcus Albus
02
Targets
TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on compound inactivated staphylococcus albus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on compound inactivated staphylococcus albus.